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continue to advance. Thus, aligning the clini-
cal practice of predictive genetic testing for 
Alzheimer’s disease with patient values and 
preferences has the potential to improve he-
althcare delivery. In this literature review, we 
discuss issues associated with people’s pre-
ferences when making a decision to test for 
AD or not.
Several issues have been identified in this li-
terature review regarding people’s preferen-
ces when making a decision to test for AD, 
which include:
 - prediction value (i.e., false-positive/false-
negative results);
 - availability of treatments that would pre-
vent or delay onset of AD;
 - anonymity/confidentiality.
The prediction value of the AD genetic test 
can help people know how confident they can 
be with the result.
INTRODUCTION
As the sixth leading cause of death in US, 
Alzheimer’s disease (AD) currently af-
fects more than 5 million Americans [1,2]. 
Worldwide, approximately 36 million people 
are living with dementia [3]. While Alzhei-
mer’s disease has an unknown etiology, high 
prevalence and no cure, it is still known to 
have a genetic link. People might be able to 
prepare themselves and their family for the di-
sease’s debilitating effects if one could obtain 
knowledge of future risk for the disease.
With the advent and increased prevalence of 
predictive genetic tests, individuals now have 
the option to investigate their future risk of 
developing diseases like AD. Even though 
genetic testing for AD is only recommen-
ded in certain cases [4], the use of predicti-
ve genetic tests is almost sure to increase as 
technology and genetic marker identification 
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ABSTRACT
With the advent of predictive genetic tests, individuals will have the option to investigate their future risk of developing 
diseases like Alzheimer’s disease (AD). This knowledge can benefit people as they start to prepare themselves as well as 
their families for the disease process.
This review discusses issues associated with people’s preferences when making a decision to test for AD or not. Several 
issues have been identified, which include prediction value (i.e., false-positive/false-negative results), availability of tre-
atments that would prevent or delay onset of AD, and anonymity/confidentiality. Literature indicates the most relevant 
issues regarding consumer preference for AD genetic testing is predictive value (accuracy). While fewer studies have 
discussed the effects of treatment availability or anonymity on consumer preference, these issues may become more im-
portant as technology continues to advance and public awareness of these issues increases. Future research in the area of 
consumer behavior with regard to predictive genetic testing is suggested.
Most previous studies regarding consumer intent and preference for AD genetic tests have used small samples, convenience 
samples, or samples which were predominantly Caucasian, female and high socioeconomic status. Additionally, effects of 
most socio-demographics on the preference for AD genetic test are unclear in the literature. Conflicting results have been 
found regarding gender, education, income, and culture. An extension of the previous work using a larger and randomized 
sample may help to provide clearer relationship between these socio-demographics and consumer preference for AD ge-
netic test.
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Treatment availability for AD impacts pe-
ople’s health outcomes, quality of life, and 
future plans.
Another important issue is anonymity/con-
fidentiality, which brings concerns about 
discrimination in health insurance and em-
ployment.
This literature review explores consumer 
preferences, which can have implications for 
individual decision making such as arranging 
for personal affairs, purchase of insurance for 
long-term care, or even family’s preparation 
for possible future illness. Previous studies 
related to people’s intention to seek AD ge-
netic testing have used various samples in-
cluding convenience samples (e.g., students, 
samples that enrolled relatives of AD pa-
tients), samples which were predominantly 
Caucasian, female and high socioeconomic 
status, or general population samples. By un-
derstanding consumer preferences, healthca-
re professionals can provide services that 
more closely fulfill patient/customer needs. 
Finally, this understanding will also assist 
policy makers as they contemplate optimal 
testing/screening strategies and related po-
licy relative to Alzheimer’s disease.
PREDICTIVE VALUE 
OF THE GENETIC TESTING 
FOR ALZHEIMER’S DISEASE
How well the test can predict the risk of de-
veloping AD plays an important role in the 
decision making process. Owing to low sen-
sitivity/specificity and uncertain causality of 
the disease, genetic risk information in AD 
testing can have predictive value as low as 
42%, which means the result will be true 
in only 42% of cases [5]. One study asked 
physicians about the minimal predictive va-
lue of AD genetic tests suitable to be used in 
clinical practice: the responses ranged from 
20% to 100% with a median of 80% [6]. As 
for the opinion from relatives of people with 
AD, Green et al. used a convenience sample 
of people aged 22-77 and found that even if 
the tests were only 60% accurate, 35% of pe-
ople surveyed would still choose to take the 
test [7]. Bassett et al. found that among of-
fspring of people with AD, only 20% would 
not obtain any predictive testing and more 
than 40% of respondents would accept tests 
with imperfect sensitivity /specificity as low 
as 30% [8]. Neumann et al. used a general 
population sample and found 45% of respon-
dents stated that they would take a predictive 
genetic test for AD when the test result has a 
90% chance to be correct [9]. One recent stu-
dy incorporated conjoint analysis in an online 
survey of the general population. This study 
revealed that accuracy was the most impor-
tant factor regarding the preference for the 
AD genetic tests, however, the accuracy of 
the tests may not need to be 100% to appe-
al to many consumers [10]. So, the literatu-
re supports, to some extent, the premise that 
consumers might accept genetic tests which 
are not 100% accurate: 80% accuracy may be 
a good enough target for AD genetic test de-
velopment [6,10].
TREATMENT AVAILABILITY 
FOR ALZHEIMER’S DISEASE
Availability of treatment options for Alzhei-
mer’s disease is also essential to people’s 
decision regarding genetic testing for AD. 
To date, there is still no cure for Alzheimer’s 
disease, but several drugs currently being 
prescribed may temporarily help with the 
symptoms and improve quality of life for 
AD patients. Complementary options such 
as mental training, physical exercise, sensory 
stimulation and regular leisure activity can 
also help to decrease behavioral problems 
[11]. With the understanding of limited tre-
atment options, 77.8% of participants still 
desired to take the test [12]. One qualitati-
ve study showed that a genetic test for AD 
could still be beneficial to at-risk individuals 
and their family by helping them cope with 
emotional responses and plan the future [13]. 
These results indicate consumers are still 
interested in AD genetic test even with the 
understanding that treatment options are li-
mited. As technology continues to advance, 
treatment options with better potential out-
comes may appear and have more impact on 
consumer preferences regarding AD genetic 
tests.
ANONYMITY/CONFIDENTIALITY 
ISSUE REGARDING THE 
GENETIC TESTING FOR 
ALZHEIMER’S DISEASE
Concerns about discrimination in health insu-
rance and employment may also influence 
one’s decision to obtain a genetic test for AD 
(refer to Table I for the comparison of pre-
vious works on people’s intention to seek AD 
genetic testing). In a study regarding reasons 
for seeking genetic susceptibility testing, Ro-
berts et al. found 34.3% of people thought it 
was risky to take a genetic test for AD becau-
se their insurance company or employer 
might find out the test results and use them to 
discriminate against the patients [12]. Neu-
mann et al. also found 31.8% of respondents 
worried about others gaining access to their 
test results [9]. The previous findings pointed 
Study Participant recruitment N. Hypothetical scenario Res (%) FGT
Green et al., 
1997 [7]
Convenience sample from: (a) family 
members and caregivers of patients 
with AD attending a regional 
symposium; (b) subjects participating 
in a study of past exposures to 
chemicals in the workplace; (c) 
volunteers from a civic organization
176 Test accuracy: No
60% 35
100% 69
Roberts et 
al., 2000 [12]
Children and siblings of patients with 
AD. Referral from geriatric medical 
care facilities and advertising in 
hospital and community in Michigan
203 Test accuracy: No
99% 58.1
85% 54.7
Treatment availability:
Prevention 96.1
Delay AD onset 77.8
Test result information: 
Less certain risk (50%) 49.5
More certain risk (95%) 63.1
Neumann et 
al., 2001 [9]
Random sample of US adults using 
random-digit-dialing techniques
314 Perfect test: zero chance to be incorrect
Imperfect test: one in ten chance to be 
incorrect
N/A No
Frost et al., 
2001 [15]
Convenience sample of 
undergraduate students in UK
449 Test result information: 
More certain (90%)
Less certain (50%)
N/A No
Roberts et 
al., 2003 [16]
Randomized controlled trial 
(Risk Evaluation and Education for 
Alzheimer Disease – REVEAL study)
Adult children of patients with AD
206 No hypothetical scenarios
Intervention arm: genetic counseling and 
risk assessment (lifetime risk estimates 
based on family history and sex ranging 
from 13% to 57%)
Control arm: risk estimates based on family 
history and sex ranging from 18% to 29%
77.7% went on to seek 
testing (overall)
Yes
Hipps et al., 
2003[17]
Convenience sample of: (a) health 
workers/family members attending 
a conference in Alabama; (b) 
healthcare workers attending a 
meeting in Florida; (c) persons in 
Georgia who were participating 
in other public health surveys; (d) 
members of church congregations/
civic organizations and participants in 
support groups/health fairs in Atlanta
452 100% accurate with treatment available to 
delay the onset of AD
80.3 No
60% accurate and cost $ 200 19.6
100% accuracy 64
80% accuracy 51
60% accuracy 30
Bassett et al., 
2004 [8]
Convenience sample of the adult 
offspring of AD patients currently 
enrolled in a genetic linkage study
518 Test accuracy: No
Sensitivity (False-positive):
 • 92% 76.3
 • 69% 68.8
 • 31% 59.9
Positive predict value:
 • 87% 65.1
 • 65% 55.0
 • 33% 47.9
Roberts et al., 
2004 [18]
Randomized controlled trial 
(REVEAL study)
Adult children of a person with 
clinically diagnosed and/or 
autopsy-confirmed AD
Self-referred:  
179
No hypothetical scenarios
Intervention arm: genetic counseling and 
risk assessment (lifetime risk estimates 
based on family history and sex ranging 
from 13% to 57%)
Control arm: risk estimates based on family 
history and sex ranging from 18% to 29%
64% went on to have ge-
notyping and received 
AD risk disclosure
Yes
Systemati-
cally  
contacted: 
110
24% went on to have ge-
notyping and received 
AD risk disclosure
Yes
Binetti et al., 
2006 [19]
Clinical trial (REVEAL study)
Italian sample: first and second 
degree relatives of patients from 
families were at least affected 
individuals, subjects were not paid
134 99% test accuracy and 95% lifetime risk 73.8 No
Less test accuracy (85%) 70.8
Immediate risk 71.5
Less certain risk information 
(50% lifetime risk)
70.0
Available treatment to delay AD onset 77.7
Available treatment to prevent AD 87.7
Huang et al. 
2011 [10]
Online panel 295 Predictive value (accuracy): 
 • 40%
 • 80%
 • 100%
Treatment availability: 
 • Cure available
 • No cure but treatment available for 
symptom relief
Result anonymity: 
 • Anonymous
 • Not anonymous
N/A No
Table I. Previous work on people’s intention to seek AD genetic testing
Res = respondents expressing probable or definite intentions to seek testing or went on to seek testing
FGT = free genetic test provided
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revealed that accuracy was the most impor-
tant factor regarding the preference for the 
AD genetic tests, however, the accuracy of 
the tests may not need to be 100% to appe-
al to many consumers [10]. So, the literatu-
re supports, to some extent, the premise that 
consumers might accept genetic tests which 
are not 100% accurate: 80% accuracy may be 
a good enough target for AD genetic test de-
velopment [6,10].
TREATMENT AVAILABILITY 
FOR ALZHEIMER’S DISEASE
Availability of treatment options for Alzhei-
mer’s disease is also essential to people’s 
decision regarding genetic testing for AD. 
To date, there is still no cure for Alzheimer’s 
disease, but several drugs currently being 
prescribed may temporarily help with the 
symptoms and improve quality of life for 
AD patients. Complementary options such 
as mental training, physical exercise, sensory 
stimulation and regular leisure activity can 
also help to decrease behavioral problems 
[11]. With the understanding of limited tre-
atment options, 77.8% of participants still 
desired to take the test [12]. One qualitati-
ve study showed that a genetic test for AD 
could still be beneficial to at-risk individuals 
and their family by helping them cope with 
emotional responses and plan the future [13]. 
These results indicate consumers are still 
interested in AD genetic test even with the 
understanding that treatment options are li-
mited. As technology continues to advance, 
treatment options with better potential out-
comes may appear and have more impact on 
consumer preferences regarding AD genetic 
tests.
ANONYMITY/CONFIDENTIALITY 
ISSUE REGARDING THE 
GENETIC TESTING FOR 
ALZHEIMER’S DISEASE
Concerns about discrimination in health insu-
rance and employment may also influence 
one’s decision to obtain a genetic test for AD 
(refer to Table I for the comparison of pre-
vious works on people’s intention to seek AD 
genetic testing). In a study regarding reasons 
for seeking genetic susceptibility testing, Ro-
berts et al. found 34.3% of people thought it 
was risky to take a genetic test for AD becau-
se their insurance company or employer 
might find out the test results and use them to 
discriminate against the patients [12]. Neu-
mann et al. also found 31.8% of respondents 
worried about others gaining access to their 
test results [9]. The previous findings pointed 
Study Participant recruitment N. Hypothetical scenario Res (%) FGT
Green et al., 
1997 [7]
Convenience sample from: (a) family 
members and caregivers of patients 
with AD attending a regional 
symposium; (b) subjects participating 
in a study of past exposures to 
chemicals in the workplace; (c) 
volunteers from a civic organization
176 Test accuracy: No
60% 35
100% 69
Roberts et 
al., 2000 [12]
Children and siblings of patients with 
AD. Referral from geriatric medical 
care facilities and advertising in 
hospital and community in Michigan
203 Test accuracy: No
99% 58.1
85% 54.7
Treatment availability:
Prevention 96.1
Delay AD onset 77.8
Test result information: 
Less certain risk (50%) 49.5
More certain risk (95%) 63.1
Neumann et 
al., 2001 [9]
Random sample of US adults using 
random-digit-dialing techniques
314 Perfect test: zero chance to be incorrect
Imperfect test: one in ten chance to be 
incorrect
N/A No
Frost et al., 
2001 [15]
Convenience sample of 
undergraduate students in UK
449 Test result information: 
More certain (90%)
Less certain (50%)
N/A No
Roberts et 
al., 2003 [16]
Randomized controlled trial 
(Risk Evaluation and Education for 
Alzheimer Disease – REVEAL study)
Adult children of patients with AD
206 No hypothetical scenarios
Intervention arm: genetic counseling and 
risk assessment (lifetime risk estimates 
based on family history and sex ranging 
from 13% to 57%)
Control arm: risk estimates based on family 
history and sex ranging from 18% to 29%
77.7% went on to seek 
testing (overall)
Yes
Hipps et al., 
2003[17]
Convenience sample of: (a) health 
workers/family members attending 
a conference in Alabama; (b) 
healthcare workers attending a 
meeting in Florida; (c) persons in 
Georgia who were participating 
in other public health surveys; (d) 
members of church congregations/
civic organizations and participants in 
support groups/health fairs in Atlanta
452 100% accurate with treatment available to 
delay the onset of AD
80.3 No
60% accurate and cost $ 200 19.6
100% accuracy 64
80% accuracy 51
60% accuracy 30
Bassett et al., 
2004 [8]
Convenience sample of the adult 
offspring of AD patients currently 
enrolled in a genetic linkage study
518 Test accuracy: No
Sensitivity (False-positive):
 • 92% 76.3
 • 69% 68.8
 • 31% 59.9
Positive predict value:
 • 87% 65.1
 • 65% 55.0
 • 33% 47.9
Roberts et al., 
2004 [18]
Randomized controlled trial 
(REVEAL study)
Adult children of a person with 
clinically diagnosed and/or 
autopsy-confirmed AD
Self-referred:  
179
No hypothetical scenarios
Intervention arm: genetic counseling and 
risk assessment (lifetime risk estimates 
based on family history and sex ranging 
from 13% to 57%)
Control arm: risk estimates based on family 
history and sex ranging from 18% to 29%
64% went on to have ge-
notyping and received 
AD risk disclosure
Yes
Systemati-
cally  
contacted: 
110
24% went on to have ge-
notyping and received 
AD risk disclosure
Yes
Binetti et al., 
2006 [19]
Clinical trial (REVEAL study)
Italian sample: first and second 
degree relatives of patients from 
families were at least affected 
individuals, subjects were not paid
134 99% test accuracy and 95% lifetime risk 73.8 No
Less test accuracy (85%) 70.8
Immediate risk 71.5
Less certain risk information 
(50% lifetime risk)
70.0
Available treatment to delay AD onset 77.7
Available treatment to prevent AD 87.7
Huang et al. 
2011 [10]
Online panel 295 Predictive value (accuracy): 
 • 40%
 • 80%
 • 100%
Treatment availability: 
 • Cure available
 • No cure but treatment available for 
symptom relief
Result anonymity: 
 • Anonymous
 • Not anonymous
N/A No
Table I. Previous work on people’s intention to seek AD genetic testing
Res = respondents expressing probable or definite intentions to seek testing or went on to seek testing
FGT = free genetic test provided
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out that anonymity might also play an impor-
tant role for decision making when obtaining 
a predictive genetic test for AD. Although the 
Genetic Information Nondiscrimination Act 
(GINA) signed by President Bush in 2008 
forbids discrimination based on genetic in-
formation in health insurance and em-
ployment, it is not clear whether people’s 
concerns about genetic discrimination have 
changed since the law passed. GINA prohi-
bits health insurers from requesting genetic 
testing from customers for decisions about 
coverage eligibility or premiums. It also 
prohibits employers from using genetic infor-
mation for hiring or discharge decisions [14].
RELATIONSHIP BETWEEN 
SOCIO-DEMOGRAPHICS AND 
PEOPLE’S ATTITUDES TOWARD 
PREDICTIVE GENETIC TESTING 
FOR ALZHEIMER’S DISEASE
The literature indicates that age, gender, edu-
cation, income, and race/cultural background 
may impact the decision for genetic testing 
for AD. Frost et al. used a college student 
sample and suggested that demand for ge-
netic AD testing was likely to be low among 
young people [15]. Others have found that 
people below the age of 60 were more likely 
to seek tests compared to people age 60 and 
above; indicating the “baby boomer” genera-
tion might want to seek more genetic infor-
mation than older generations [18].
Different results have been found regarding 
the role of gender for genetic testing for AD. 
Roberts et al. found that men expressed more 
interest in being tested than women [12]. 
Bassett et al. showed that men tend to accept 
tests with higher error rates [8]. In contrast, 
women were the majority in a study asking 
consumers to take part in a clinical trial that 
provided free genetic testing [18]. Other stu-
dies have suggested that gender was not as-
sociated with the desire to be tested for AD 
[9,15].
The effect of education on the desire to obtain 
genetic testing for AD is unclear. In one stu-
dy, Green et al. found that subjects who ex-
pressed the desire to obtain genetic testing 
for AD had lower educational levels [7]. Ho-
wever, Roberts et al. found that respondents 
with a college level education were more li-
kely to seek testing [18]. Educational level 
may also impact test acceptance based on 
sensitivity/specificity. One study showed that 
respondents with lower education levels were 
more likely to accept tests for AD which had 
higher error rates [8].
Roberts et al. found income was not associa-
ted with the desire to seek genetic testing for 
AD [18]. Neumann et al., however, found that 
income was associated with the likelihood of 
seeking a genetic test. Respondents with lo-
wer incomes (household income less than $ 
30,000) were more likely to be interested in 
taking the genetic tests [9].
There were also conflicting results about 
cultural effects on the desires to obtain ge-
netic testing for AD. Binetti et al. showed 
that Italians were more likely to obtain an 
AD genetic test than Americans and indica-
ted the culture background may influence the 
desire to obtain the AD genetic testing [19]. 
Another study suggested African Americans 
showed less interest in genetic testing for AD 
when compared to whites [20]. While these 
two studies found that culture may have an 
effect, Neumann et al., however, showed that 
desire to take a genetic test for AD was con-
stant across different races including whites, 
African American and Hispanic in the US . 
Neumann et al. also showed that people with 
AD family history or AD care-giving expe-
rience were more likely to take AD genetic 
test, although the differences were not stati-
stically significant [9].
Conflicting, unclear, or non-significant re-
sults have been found in the literature regar-
ding the relationship between various social-
demographics and consumers preferences 
for genetic tests. Studies using larger, more 
generalizable, randomized samples are nee-
ded to provide a better understanding of con-
sumer preferences with respect to predictive 
genetic tests.
VALUATION OF PREDICTIVE 
GENETIC TESTING FOR 
ALZHEIMER’S DISEASE 
There has been limited research evaluating 
people’s willingness-to-pay for genetic te-
sting for AD. This is likely due to the fact that 
the test is still not recommended for clinical 
use. However, research on the community’s 
willingness-to-pay (WTP) for genetic testing 
for AD can have implications for research de-
velopment, health policy, and clinical practi-
ce. Neumann et al. determined people’s WTP 
for genetic testing for AD by using a double-
bounded, dichotomous choice contingent va-
luation method. Respondents were randomi-
zed to one of four bidding amounts: $ 100, $ 
500, $ 1000, $ 1500 and answered whether 
they would or would not take a predictive test 
with 100% accuracy. If respondents answe-
red yes to the initial bidding, they were asked 
whether they would pay double that amount. 
If they answered no to the initial bidding, 
they were asked whether they would pay 
half of the amount. Their study showed that 
Study Participant recruitment N.
Response 
rate
Mean 
age and 
range
Gender  
(% female)
Race  
(% white)
Annual house-
hold income
AD care-giv-
ing history*
FGT
Green et al., 
1997 [7]
Convenience sample from: 
(a) family members and 
caregivers of patients with 
AD attending a regional 
symposium; (b) subjects 
participating in a study of 
past exposures to chemical 
s in the workplace; (c) 
volunteers from a civic
176 54 45
(22-77)
75 70 N/A N/A No
Roberts et 
al., 2000 [12]
Children and siblings of 
patients with AD. Referral 
from Geriatric medical care 
facilities and advertising in 
hospital and community in 
Michigan
203 N/A 53.5
(30-92)
75.4 95.6 74.7% had an 
income over 
$ 40,000
93.1 No
Neumann et 
al., 2001 [9]
Random sample of US 
adults using random-digit-
dialing techniques
314 47 43.3 62.4 73.0 48.1% had 
an income 
of $ 30,000-
75,000
24 No
Frost et al., 
2001 [15]
Convenience sample of 
undergraduate students 
in UK
449 87.5 All 
college 
student 
55.68 N/A N/A N/A No
Roberts et 
al., 2003 [16]
Randomized controlled 
trial (Risk Evaluation and 
Education for Alzheimer 
Disease – REVEAL study)
Adult children of patients 
with AD
206 N/A 52.8
(30-78)
72.3 94.7 Median 
household 
income: 
$ 70,000-
99,999
75 Yes
Hipps et al., 
2003 [17]
Convenience sample of: 
(a) health workers/family 
members attending a 
conference in Alabama; 
(b) healthcare workers 
attending a meeting 
in Florida; (c) persons 
in Georgia who were 
participating in other public 
health surveys; (d) members 
of church congregations/
civic organizations and 
participants in support 
groups/health fairs in Atlanta
452 N/A 47 78 61 Median 
household 
income: 
$ 40,000-
59,999
20 No
Bassett et 
al., 2004 [8]
Convenience sample of 
the adult offspring of AD 
patients currently enrolled in 
a genetic linkage study
518 78 40.4% 
in the 
range of 
50-59
(18-78)
59.7 96.3 75% had a 
income over 
$ 35,000
25 No
Roberts et 
al., 2004 [18]
Randomized controlled trial 
(REVEAL study)
Adult children of a 
person with clinically 
diagnosed and/or autopsy-
confirmed AD
Self-
referred: 
179
N/A 52.5
(31-82)
78.8 91.1 Median: 
$ 70,000-
99,999
N/A Yes
System-
atically 
contacted: 
110
N/A 57.9
(30-82)
58.2 97.3 Median: 
$ 50,000-
69,999
N/A Yes
Gooding et 
al., 2006 [13]
Adult children of people 
with AD enrolled in REVEAL 
study (REVEAL-QRI study)
60 N/A 54
(37-76)
87 95 Median: 
70,000-
99,999
N/A Yes
Binetti et al., 
2006 [19]
Clinical trial (REVEAL study)
Italian sample: first and 
second-degree relatives of 
patients from families were 
at least affected individuals, 
subject were not paid
Compare to American 
sample [12]: one family 
member with AD, subjects 
were paid 
134 54.5 47.5 57 100% 
Italian 
N/A 58% No
Moscarillo 
et al., 2007 
[21]
Convenience sample of 
unaffected relatives being 
followed as part of an 
ongoing genetic linkage 
study
Pilot  
survey: 57
87.7 73.1
(38-93)
53 100 N/A N/A No
Focus 
group:16
N/A 40-70 68.8 62.5 N/A N/A No
Huang et al, 
2011 [10]
Online panel 295 N/A 44.7
(18-64)
49 86 47% had 
an annual 
income over 
$ 50,000
16 No
Table II. Comparison of the sample description
* % had served as caregiver
FGT = Free genetic test provided
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AD [18]. Neumann et al., however, found that 
income was associated with the likelihood of 
seeking a genetic test. Respondents with lo-
wer incomes (household income less than $ 
30,000) were more likely to be interested in 
taking the genetic tests [9].
There were also conflicting results about 
cultural effects on the desires to obtain ge-
netic testing for AD. Binetti et al. showed 
that Italians were more likely to obtain an 
AD genetic test than Americans and indica-
ted the culture background may influence the 
desire to obtain the AD genetic testing [19]. 
Another study suggested African Americans 
showed less interest in genetic testing for AD 
when compared to whites [20]. While these 
two studies found that culture may have an 
effect, Neumann et al., however, showed that 
desire to take a genetic test for AD was con-
stant across different races including whites, 
African American and Hispanic in the US . 
Neumann et al. also showed that people with 
AD family history or AD care-giving expe-
rience were more likely to take AD genetic 
test, although the differences were not stati-
stically significant [9].
Conflicting, unclear, or non-significant re-
sults have been found in the literature regar-
ding the relationship between various social-
demographics and consumers preferences 
for genetic tests. Studies using larger, more 
generalizable, randomized samples are nee-
ded to provide a better understanding of con-
sumer preferences with respect to predictive 
genetic tests.
VALUATION OF PREDICTIVE 
GENETIC TESTING FOR 
ALZHEIMER’S DISEASE 
There has been limited research evaluating 
people’s willingness-to-pay for genetic te-
sting for AD. This is likely due to the fact that 
the test is still not recommended for clinical 
use. However, research on the community’s 
willingness-to-pay (WTP) for genetic testing 
for AD can have implications for research de-
velopment, health policy, and clinical practi-
ce. Neumann et al. determined people’s WTP 
for genetic testing for AD by using a double-
bounded, dichotomous choice contingent va-
luation method. Respondents were randomi-
zed to one of four bidding amounts: $ 100, $ 
500, $ 1000, $ 1500 and answered whether 
they would or would not take a predictive test 
with 100% accuracy. If respondents answe-
red yes to the initial bidding, they were asked 
whether they would pay double that amount. 
If they answered no to the initial bidding, 
they were asked whether they would pay 
half of the amount. Their study showed that 
Study Participant recruitment N.
Response 
rate
Mean 
age and 
range
Gender  
(% female)
Race  
(% white)
Annual house-
hold income
AD care-giv-
ing history*
FGT
Green et al., 
1997 [7]
Convenience sample from: 
(a) family members and 
caregivers of patients with 
AD attending a regional 
symposium; (b) subjects 
participating in a study of 
past exposures to chemical 
s in the workplace; (c) 
volunteers from a civic
176 54 45
(22-77)
75 70 N/A N/A No
Roberts et 
al., 2000 [12]
Children and siblings of 
patients with AD. Referral 
from Geriatric medical care 
facilities and advertising in 
hospital and community in 
Michigan
203 N/A 53.5
(30-92)
75.4 95.6 74.7% had an 
income over 
$ 40,000
93.1 No
Neumann et 
al., 2001 [9]
Random sample of US 
adults using random-digit-
dialing techniques
314 47 43.3 62.4 73.0 48.1% had 
an income 
of $ 30,000-
75,000
24 No
Frost et al., 
2001 [15]
Convenience sample of 
undergraduate students 
in UK
449 87.5 All 
college 
student 
55.68 N/A N/A N/A No
Roberts et 
al., 2003 [16]
Randomized controlled 
trial (Risk Evaluation and 
Education for Alzheimer 
Disease – REVEAL study)
Adult children of patients 
with AD
206 N/A 52.8
(30-78)
72.3 94.7 Median 
household 
income: 
$ 70,000-
99,999
75 Yes
Hipps et al., 
2003 [17]
Convenience sample of: 
(a) health workers/family 
members attending a 
conference in Alabama; 
(b) healthcare workers 
attending a meeting 
in Florida; (c) persons 
in Georgia who were 
participating in other public 
health surveys; (d) members 
of church congregations/
civic organizations and 
participants in support 
groups/health fairs in Atlanta
452 N/A 47 78 61 Median 
household 
income: 
$ 40,000-
59,999
20 No
Bassett et 
al., 2004 [8]
Convenience sample of 
the adult offspring of AD 
patients currently enrolled in 
a genetic linkage study
518 78 40.4% 
in the 
range of 
50-59
(18-78)
59.7 96.3 75% had a 
income over 
$ 35,000
25 No
Roberts et 
al., 2004 [18]
Randomized controlled trial 
(REVEAL study)
Adult children of a 
person with clinically 
diagnosed and/or autopsy-
confirmed AD
Self-
referred: 
179
N/A 52.5
(31-82)
78.8 91.1 Median: 
$ 70,000-
99,999
N/A Yes
System-
atically 
contacted: 
110
N/A 57.9
(30-82)
58.2 97.3 Median: 
$ 50,000-
69,999
N/A Yes
Gooding et 
al., 2006 [13]
Adult children of people 
with AD enrolled in REVEAL 
study (REVEAL-QRI study)
60 N/A 54
(37-76)
87 95 Median: 
70,000-
99,999
N/A Yes
Binetti et al., 
2006 [19]
Clinical trial (REVEAL study)
Italian sample: first and 
second-degree relatives of 
patients from families were 
at least affected individuals, 
subject were not paid
Compare to American 
sample [12]: one family 
member with AD, subjects 
were paid 
134 54.5 47.5 57 100% 
Italian 
N/A 58% No
Moscarillo 
et al., 2007 
[21]
Convenience sample of 
unaffected relatives being 
followed as part of an 
ongoing genetic linkage 
study
Pilot  
survey: 57
87.7 73.1
(38-93)
53 100 N/A N/A No
Focus 
group:16
N/A 40-70 68.8 62.5 N/A N/A No
Huang et al, 
2011 [10]
Online panel 295 N/A 44.7
(18-64)
49 86 47% had 
an annual 
income over 
$ 50,000
16 No
Table II. Comparison of the sample description
* % had served as caregiver
FGT = Free genetic test provided
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respondents were willing to pay $ 170 for a 
predictive test which had a one-in-ten chance 
of being incorrect and $ 324 for a perfectly 
predictive test [9]. Another study which also 
surveyed the general population, showed that 
the median willingness-to-pay for a perfect 
scenario (Accuracy 100%, a cure is available, 
test result is anonymous) was $ 100 (mean 
WTP was $ 276). It also showed that even 
though there was no cure available for AD, 
respondents were still willing to pay for the 
test if the accuracy were at least 80% [10]. 
CONCLUSION
The literature identifies the most relevant is-
sues regarding consumer preference for AD 
genetic testing including: predictive value 
(accuracy), treatment availability and ano-
nymity. Most previous studies have exami-
ned the relationship between predictive value 
and consumer preferences for taking an AD 
genetic test. It has been shown that consu-
mers may be more concerned with the pre-
dictive value of AD genetic test than either 
anonymity or the availability of treatment 
options. Since consumer preference for AD 
genetic testing seems to be driven by the tests 
ability to correctly predict the disease, gene-
tic test developers should focus on strategies 
that improve predictive accuracy to at least 
80%. While fewer studies discussed the ef-
fects of treatment availability or anonymity 
on consumer preference, these issues may 
become more important as technology conti-
nues to advance or public awareness of these 
issues increases.
Most previous studies regarding consumer 
intent and preference for AD genetic test 
have used small samples, convenience sam-
ples (e.g. students, samples that enrolled rela-
tives of AD patients), or samples which were 
predominantly Caucasian, female and high 
socioeconomic status (refer to Table II for 
sample comparison). Additionally, the effects 
of most socio-demographics on the preferen-
ce for AD genetic test are unclear in the li-
terature. Conflicting results have been found 
regarding gender, education, income, and 
culture. More research is needed which will 
add to the previous work using more repre-
sentative, randomized samples. This should 
help to provide a clearer understanding of 
the relationship between socio-demographics 
variables and consumer preferences for AD 
genetic test.
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